GlassScriptPhysician profile
Kevin Wong
NPI 1477523991
$38,075.43
in general payments reported to CMS, 2019-2025
64 companies · $4,500 in 2025
The $4,500 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,767 · 2020: $4,514 · 2021: $6,194 · 2022: $5,657 · 2023: $5,858 · 2024: $5,586 · 2025: $4,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $59.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,884.05 |
| Education | $59.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,640.76 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,628.47 | 2019-2025 | Jardiance, Spiriva Respimat, Ofev |
| Astrazeneca Pharmaceuticals LP | $4,493.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,652.19 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $2,266.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $1,397.34 | 2021-2025 | |
| Pfizer INC. | $1,211.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,149.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Cmp Pharma, INC. | $1,088.10 | 2021-2025 | Norliqva, Atorvaliq, Tadliq |
| Gilead Sciences, INC. | $1,044.07 | 2019-2025 | |
| Amgen INC. | $1,017.93 | 2020-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $992.22 | 2019-2025 | Verquvo, Belsomra, Januvia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $944.18 | 2019-2024 | Lifevest |
| Abbvie INC. | $902.44 | 2019-2025 | Linzess, Vraylar, Creon |
| Novartis Pharmaceuticals Corporation | $898.30 | 2019-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.